Loading organizations...
§ Private Profile · Malvern, PA, USA
Specialty pharmaceutical company developing Valchlor, a mechlorethamine gel, for early-stage mycosis fungoides (CTCL).
Ceptaris Therapeutics was a Malvern, Pennsylvania-based specialty pharmaceutical company that focused on developing and commercializing targeted therapies for rare dermatological oncology conditions. The organization primarily advanced Valchlor, a proprietary topical gel formulation of mechlorethamine specifically designed to treat patients suffering from early-stage mycosis fungoides, which is a rare type of cutaneous T-cell lymphoma. Operating as a NeXeption portfolio company, the enterprise successfully raised over $40 million in venture capital funding to finance its drug development operations and clinical trials. This financial backing was secured from institutional investors including lead investor Vivo Ventures and Third Point Ventures. Following the successful advancement of its lead program through phase III clinical testing and subsequent FDA approval, the business was acquired by Actelion Pharmaceuticals in August 2013. The pharmaceutical enterprise was established by founder Robert Alonso.
Ceptaris Therapeutics has raised $54.0M across 4 funding rounds.
Ceptaris Therapeutics has raised $54.0M in total across 4 funding rounds.
# Ceptaris Therapeutics: A Specialty Pharmaceutical Company, Not a Technology Company
The premise of your query contains an inaccuracy: Ceptaris Therapeutics is a specialty pharmaceutical company, not a technology company.[1][2] It develops proprietary drug formulations for rare diseases rather than building software, hardware, or digital platforms.
Ceptaris Therapeutics is a specialty pharmaceutical company focused on developing treatments for rare cancers, specifically cutaneous T-cell lymphomas (CTCL).[1][2] The company's primary product is Valchlor, a proprietary gel formulation of mechlorethamine designed to treat early-stage mycosis fungoides, a type of CTCL.[1]
The company serves patients with rare skin cancers who lack effective topical treatment options. Its core mission is to revolutionize treatment for early-stage mycosis fungoides by offering the first topical mechlorethamine product available for this indication.[2] Ceptaris operated as an independent entity until August 2013, when it was acquired by Actelion Pharmaceuticals, a Swiss pharmaceutical company listed on the SIX Swiss Exchange.[1]
Ceptaris was established in 2002 in Malvern, Pennsylvania.[4] The company was founded with the specific objective of developing a novel topical formulation of an existing chemotherapy agent (mechlorethamine) for a rare cancer indication where treatment options were limited.
The company gained traction through venture capital funding, securing $15 million in February 2012 through Oxford Finance and Silicon Valley Bank, followed by $10 million in Series D-1 funding in June 2012 from investors including Aperture Venture Partners, BioAdvance, Palo Alto Investors, Third Point Ventures, and Vivo Ventures.[2] This funding trajectory demonstrated investor confidence in the company's drug development approach and market opportunity.
Ceptaris exemplifies the specialty pharmaceutical model—focusing on rare diseases and niche patient populations where unmet medical needs create market opportunities despite smaller patient bases. The company's acquisition by Actelion in 2013 reflects how larger pharmaceutical companies strategically acquire specialized biotech firms to expand their rare disease portfolios and accelerate market entry for novel formulations.
As a subsidiary of Actelion (now part of Johnson & Johnson following Actelion's acquisition), Ceptaris's independent trajectory concluded with its 2013 acquisition. The company's legacy demonstrates how venture-backed specialty pharma companies can achieve successful exits by solving specific clinical problems in rare disease spaces—a model that continues to attract investment in the biotech ecosystem today.
Ceptaris Therapeutics has raised $54.0M across 4 funding rounds. Most recently, it raised $10.0M Series D in June 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2012 | $10M Series D | — | Frazier Healthcare Partners, Aperture Venture Partners, BioAdvance, Burrill & Company, Osage Venture Partners, Palo Alto Investors, Third Point, Vivo Ventures | Announced |
| Feb 21, 2012 | $15M Debt Financing | Oxford Finance, Silicon Valley Bank | — | Announced |
| Aug 1, 2011 | $14M Series D | — | Frazier Healthcare Partners, Aperture Venture Partners, Burrill & Company, Palo Alto Investors, Vivo Ventures | Announced |
| Nov 1, 2007 | $15M Series C | — | Frazier Healthcare Partners | Announced |
Ceptaris Therapeutics has raised $54.0M in total across 4 funding rounds.
Ceptaris Therapeutics's investors include Frazier Healthcare Partners, Aperture Venture Partners, BioAdvance, Burrill & Company, Osage Venture Partners, Palo Alto Investors, Third Point, Vivo Ventures, Oxford Finance, Silicon Valley Bank.